GammaDelta Therapeutics Secures Seed Funding from Abingworth

GammaDelta Therapeutics, a UK-based immunotherapy company focused on developing immunotherapies for cancer based on gamma delta (γδ) cells, has received seed funding from Abingworth, an international investment group dedicated to life sciences

The company will use the funds to advance its programs into the clinic

Founded on pioneering research by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute, funded in part by Cancer Research UK, GammaDelta Therapeutics is being incubated at Abingworth’s London office.